← Back to Search

Platelet Rich Plasma

PRP/Saline for Male Pattern Baldness

N/A
Waitlist Available
Led By Jerry Shapiro, MD
Research Sponsored by Vancouver General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial will test if injecting platelet-rich plasma (PRP) into the scalp can help people with androgenetic alopecia (a common type of hair loss) regrow hair. PRP is made from a person's own blood and contains high levels of natural growth factors. The goal is to see if these growth factors can stimulate hair growth without the side effects of current treatments. PRP has shown promising results in previous studies for treating androgenetic alopecia by stimulating hair growth through its high levels of natural growth factors.

Eligible Conditions
  • Male Pattern Baldness

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

1Treatment groups
Experimental Treatment
Group I: PRP/SalineExperimental Treatment1 Intervention
Same patient will be injected with PRP and normal saline. Each one will be inject on half head.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PRP
2014
Completed Phase 4
~1860

Find a Location

Who is running the clinical trial?

Vancouver General HospitalLead Sponsor
40 Previous Clinical Trials
19,595 Total Patients Enrolled
Jerry Shapiro, MDPrincipal InvestigatorProfessor
2 Previous Clinical Trials
120 Total Patients Enrolled
~2 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top